Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P12314

UPID:
FCGR1_HUMAN

ALTERNATIVE NAMES:
Fc-gamma RI; Fc-gamma RIA

ALTERNATIVE UPACC:
P12314; P12315; Q5QNW7; Q92495; Q92663

BACKGROUND:
High affinity immunoglobulin gamma Fc receptor I, known alternatively as Fc-gamma RI and Fc-gamma RIA, is integral to immune defense mechanisms. It binds with high affinity to the Fc region of immunoglobulins gamma, facilitating both innate and adaptive immune responses. Its function in triggering antibody-dependent cellular cytotoxicity (ADCC) against virus-infected cells underscores its importance in immune surveillance and response.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of High affinity immunoglobulin gamma Fc receptor I unveils potential avenues for therapeutic intervention. As a critical mediator of immune responses, targeting this receptor could lead to innovative treatments for managing immune-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.